Angus Lauder, a former executive at the UK’s leading cancer charity, has been named director of business development at Storm Therapeutics Ltd to help manage that company’s portfolio of epigenetic medicines. Dr Lauder was previously associate director of business management and transactions at Cancer Research UK Commercial Partnerships (formerly Cancer Research Technology). He obtained a PhD in molecular and cellular biology from the Institute of Cancer Research, University of London, before doing post-doctoral research at the MRC Laboratory of Molecular Biology in Cambridge, UK.
Storm Therapeutics announced the appointment on 20 April 2020.
Copyright 2020 Evernow Publishing Ltd.